Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less

Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
BMC Cancer (Impact Factor: 3.32). 10/2010; 10:557. DOI: 10.1186/1471-2407-10-557
Source: PubMed

ABSTRACT Whether a systemic adjuvant treatment is needed is an area of controversy in patients with node-negative early breast cancer with tumor size of ≤1 cm, including T1mic.
We performed a retrospective analysis of clinical and pathology data of all consecutive patients with node-negative T1mic, T1a, and T1b invasive ductal carcinoma who received surgery between Jan 2000 and Dec 2006. The recurrence free survival (RFS) and risk factors for recurrence were identified.
Out of 3889 patients diagnosed with breast cancer, 375 patients were enrolled (T1mic:120, T1a:93, T1b:162). Median age at diagnosis was 49. After a median follow up of 60.8 months, 12 patients developed recurrences (T1mic:4 (3.3%), T1a:2 (2.2%), T1b:6 (3.7%)), with a five-year cumulative RFS rate of 97.2%. Distant recurrence was identified in three patients. Age younger than 35 years (HR 4.91; 95% CI 1.014-23.763, p = 0.048) and triple negative disease (HR 4.93; 95% CI 1.312-18.519, p = 0.018) were significantly associated with a higher rate of recurrence. HER2 overexpression, Ki-67, and p53 status did not affect RFS.
Prognosis of node-negative breast cancer with T1mic, T1a and T1b is excellent, but patients under 35 years of age or with triple negative disease have a relatively high risk of recurrence.

  • Oncologie 12/2013; 15(12). DOI:10.1007/s10269-013-2344-4 · 0.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Small (T1a, b), lymph node negative breast tumors represent an entity diagnosed with increasing frequency due to the implementation of wide-scale screening programs. Patients bearing such tumors usually exhibit favorable long-term outcomes, with low breast cancer mortality rates at 10 years, even in the absence of adjuvant chemotherapy. However, most available data derive from retrospective studies. Additionally, a subset of patients with these tumors experience recurrence of the disease, indicating that early tumor stage itself is not a sufficient prognosticator. It is of paramount importance to refine the prognosis of this population, identifying patients with high risk of recurrence, for whom adjuvant treatment is needed. The underlying biology of the disease provides relevant information, such as grade and status of hormone receptors and HER-2 (human epidermal growth factor receptor 2), with high grade, triple negative and HER-2-positive tumors having worse prognosis. Additionally, multigene signatures may improve further the prognostication of patients with small, node negative breast cancers. Further research for this increasingly frequent group of patients is urgently needed, so that better informed clinical decision making, in particular regarding adjuvant chemotherapy, can occur.
    Cancer Treatment Reviews 10/2014; 40(10). DOI:10.1016/j.ctrv.2014.09.004 · 6.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Patients with small node-negative breast tumors, who are younger, or have human epidermal growth factor receptor 2 (HER2)-positive or triple negative breast cancer (TNBC) subtypes, are at increased recurrence risk. Concurrently, systemic treatment recommendations have evolved. Less is known about how frequently cytotoxic chemotherapy is given to these patients. Mastectomy rates have also increased. This study reports recent incidence of T1a,bN0M0 breast cancer and the characteristics associated with chemotherapy delivery and surgery selected. Patients and Methods This retrospective cohort is comprised of invasive female breast cancers diagnosed with AJCC Stage T1a,bN0M0 during 2010-2012 from the Iowa Surveillance, Epidemiology and End Results (SEER) Cancer Registry. Chemotherapy use and surgery were identified by the registry. Univariate and multivariate analysis were performed to determine patient differences across subtype and factors associated with treatment. Results The study included 1,687 patients. This represented 27.6% of all AJCC Stage I(a-c)-III breast cancer in 2010-2012, up from 18% in 1990 (P<0.0001). Of 1,456 patients with known subtype, 8.8% and 6.4% had HER2-positive and TNBC disease, respectively. Chemotherapy was given to 7.5% of women with T1aN0M0 and 12.7% of T1bN0M0 tumors. Likelihood of systemic treatment was associated with breast cancer subtype, tumor differentiation and age in a multivariate model. Mastectomy rate was 31.8%. Conclusion Small, node-negative breast cancers continue to grow significantly as a percent of invasive breast cancer diagnoses. In 2010-2012, in Iowa, systemic chemotherapy correlated with risk factors associated with recurrence: age, subtype, and tumor differentiation. Relatively high rates of mastectomy were seen.
    Clinical Breast Cancer 08/2014; 15(1). DOI:10.1016/j.clbc.2014.07.009 · 2.63 Impact Factor

Full-text (4 Sources)

Available from
May 22, 2014